New hope for tough breast cancer: experimental drug challenges standard chemo
NCT ID NCT06279364
Summary
This study is testing whether a new drug called SKB264 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has spread or returned and cannot be removed by surgery. It will involve 524 patients who have not yet received treatment for their advanced cancer. Researchers will compare how long patients live and how long their cancer stays controlled on the new drug versus standard chemotherapy options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.